DOT1L expression is reduced in high-glucose conditions. Its overexpression protects against podocyte injury by upregulating PLCL1, which enhances fatty acid oxidation and reduces lipogenesis, mitigating podocyte damage in DKD. The gene discussed is DOT1L; the disease is diabetic kidney disease.